Galectin

半乳凝素 (Galectin) 包括一类可溶性 β-半乳糖苷结合蛋白,可调节细胞生长、分化、凋亡和免疫反应等关键生物学过程。

在动物界已鉴定出 16 种半乳凝素基因,其中 12 种在人类中表达。半乳凝素通常根据其结构分为三类:(i) 原型半乳凝素(半乳凝素-1 (Gal1)、Gal2、Gal5、Gal7、Gal10、Gal11、Gal 13、Gal14 和 Gal15),其特征在于单个 CRD,可充当单体或形成同型二聚体;(ii) 嵌合半乳凝素 Gal3(此类中唯一的成员),具有单个 CRD 和较大的氨基末端结构域,有助于形成寡聚体;(iii) 串联重复半乳凝素,具有两个通过小肽结构域连接的 CRD;该组包括 Gal4、Gal6、Gal8、Gal9 和 Gal12。最近,半乳糖凝集素被认为是主要的治疗决定因素,可赋予对多种抗癌方式(包括化疗、放疗、靶向治疗、抗血管生成治疗和免疫疗法)的敏感性或抵抗力。

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
F3-PEG8-RiboTAC

F3-PEG8-RiboTAC 是一种可特异性降解致癌基因 LGALS1 mRNA 的 RiboTAC,能诱导肿瘤细胞凋亡 (apoptosis) 并抑制侵袭,具有抗肿瘤活性,可用于白血病、三阴性乳腺癌等肿瘤的研究 (RNase L ligand (MS-G88099); RNA binder (MS-B47953); Linker (MS-U70707))。

Degrader
F3-PEG8-RiboTAC

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础